Publications

MST-188 Data Presented at 8th Annual Sickle Cell Disease Research & Educational Symposium (April 11, 2014)

Effect of Purified Poloxamer 188 or Various Dextrans on Erythrocyte Sedimentation Rate in Patients with Sickle Cell Disease


MST-188 Data Presented at the National Institutes of Health Annual Sickle Cell Disease Research Clinical Meeting (August 21, 2013)

EPIC – An Ongoing Pivotal Phase 3 Study in Patients with Sickle Cell Disease


MST-188 Data Presented at 7th Annual Sickle Cell Disease Research & Educational Symposium (April 17, 2013)

Is There a Role for a Rheologic Agent in Transfusion?
Poster presented by R. Martin Emanuele, Ph.D., Senior Vice President, Development

Evaluation of Purified Poloxamer 188 in Children (EPIC) – Key Design Considerations
Poster presented by Santosh J. Vetticaden, Ph.D., M.D., Chief Medical Officer

 

 

News

Click here to view our latest press releases, SEC filings, and information about company events, media, and analyst coverage. read more

Technology

Click here to learn more about our lead product candidate, MST-188, as well as our other technologies. read more

Clinical Trials

We have initiated a Phase 3 clinical study of MST-188 for the treatment of sickle cell disease. See our Clinical Trials page for more info. read more